

Journal of Visualized Experiments

Detection of low copy number integrated viral DNA formed by in vitro Hepatitis B Virus infection --Manuscript Draft--

Article Type:	Invited Methods Article - JoVE Produced Video
Manuscript Number:	JoVE58202R2
Full Title:	Detection of low copy number integrated viral DNA formed by in vitro Hepatitis B Virus infection
Keywords:	DNA integration; Myrcludex B; hepatocellular carcinoma; double-stranded linear DNA; inverse nested PCR; virus entry; viral persistence
Corresponding Author:	Thomas Tu Universitätsklinikum Heidelberg Department für Infektiologie Heidelberg, Baden-Württemberg GERMANY
Corresponding Author's Institution:	Universitätsklinikum Heidelberg Department für Infektiologie
Corresponding Author E-Mail:	Thomas.Tu@med.uni-heidelberg.de
First Author:	Thomas Tu
Other Authors:	Stephan Urban
Author Comments:	
Additional Information:	
Question	Response
If this article needs to be "in-press" by a certain date, please indicate the date below and explain in your cover letter.	

TITLE:

Detection of Low Copy Number Integrated Viral DNA Formed by *In Vitro* Hepatitis B Infection

AUTHORS AND AFFILIATIONS:

Thomas Tu^{1,2}, Stephan Urban^{1,3}

¹Department of Infectious Diseases, Molecular Virology, Heidelberg University Hospital, Germany

²Gastroenterology and Liver Research Laboratory, Ingham Institute, Liverpool, NSW, Australia

³German Center for Infection Research (DZIF), Partner Site Heidelberg, Heidelberg, Germany

Corresponding Author:

Thomas Tu (Thomas.Tu@med.uni-heidelberg.de)

Email for Co-author:

Stephan Urban (Stephan.Urban@med.uni-heidelberg.de)

KEYWORDS:

HBV DNA integration, Myrcludex B, hepatocellular carcinoma, double-stranded linear DNA, inverse nested PCR, virus entry, viral persistence

SUMMARY:

We describe here the *in vitro* generation of HBV DNA via a Hepatitis B virus infection system and the highly sensitive detection of its (1-2 copies) integration using inverse nested PCR.

ABSTRACT:

Hepatitis B Virus (HBV) is a common blood-borne pathogen causing liver cancer and liver cirrhosis resulting from chronic infection. The virus generally replicates through an episomal DNA intermediate; however, integration of HBV DNA fragments into the host genome has been observed, even though this form is not necessary for viral replication. The exact purpose, timing, and mechanism(s) by which HBV DNA integration occurs is not yet clear, but recent data show that it occurs very early after infection. Here, the *in vitro* generation and detection of HBV DNA integrations are described in detail. Our protocol specifically amplifies single copies of virus-cell DNA integrations and allows both absolute quantification and single-base pair resolution of the junction sequence. This technique has been applied to various HBV-susceptible cell types (including primary human hepatocytes), to various HBV mutants, and in conjunction with various drug exposures. We foresee this technique becoming a key assay to determine the underlying molecular mechanisms of this clinically relevant phenomenon.

INTRODUCTION:

HBV is a double-stranded DNA virus that can cause life-long chronic infection, leading to liver cirrhosis and hepatocellular carcinoma (HCC)¹⁻³. While there are multiple molecular mechanisms driving HBV persistence⁴ (*e.g.*, high stability of the epigenetic viral transcriptional template, evasion of immune surveillance, and low turnover of hepatocytes in the liver) and its associated risk of HCC initiation^{5,6} (*e.g.*, chronic inflammation and activation of cellular stress pathways),

HBV DNA integration into the host cell genome (a reported mechanism for both of these phenomena) has been poorly studied. A major reason is the lack of suitable *in vitro* infection systems for HBV that allow reliable detection of integration events. Here, we describe a recently-developed protocol for both *in vitro* generation and detection of HBV DNA integrations that can be used to elucidate the underlying molecular mechanisms and consequences thereof.

HBV replication and the formation of HBV DNA integration has been previously reviewed in detail⁷. Briefly, HBV enters hepatocytes using the Sodium Taurocholate Co-transporting Peptide (NTCP) as the main cellular receptor for infection^{8,9}. The HBV nucleocapsids containing the HBV-relaxed circular DNA (rcDNA) genome enters the nucleus, where the rcDNA is converted into episomal covalently closed circular DNA (cccDNA). The nuclear cccDNA acts as the transcriptional template for viral mRNAs and pre-genomic RNA (pgRNA)¹⁰. HBV polymerase and pgRNA are then packaged into newly-formed nucleocapsids (composed of HBV core protein dimers). HBV pgRNA is reverse-transcribed within the nucleocapsid, resulting in either an rcDNA genome or a double-stranded linear DNA (dsDNA) genome^{11,12}. These mature nucleocapsids containing HBV DNA genomes are finally enveloped and exported as virions.

Infection of hepatocytes by enveloped particles containing dsDNA molecules can result in viral integration into the host cell genome¹³, leading to replication-incompetent forms of HBV DNA^{7,14,15}. HBV DNA integration occurs at the site of chromosomal double-stranded DNA breaks¹⁵. Accumulating evidence suggests that each integration event occurs in an essentially random position within the host cell genome. In addition, HBV DNA integration occurs somewhat rarely, at a rate of 1 per 10000 cells^{13,16-18}. Important questions regarding HBV DNA integration remain unanswered, particularly regarding the exact molecular pathways involved, the dependence on viral and host factors, the viral antigens expressed from integrated forms, and their possible contribution to viral persistence⁷. We have set up an *in vitro* model to shed light on some of these questions.

The rarity of HBV DNA integration events (both with respect to integration rate per cell and to the copy number of each unique integration) in *in vitro* HBV infection models make them challenging to detect. Cell mitosis is limited in our *in vitro* system, as dividing cells do not support efficient infection. Thus, unlike in patient liver tissues where significant clonal expansion of hepatocytes occurs¹⁶⁻¹⁸, very few (1 to 2) copies of each integration are present in a given pool of cells infected *in vitro*. We have also found that integration mainly occurs during the initial infection of hepatocytes (and not continuously in chronically-infected hepatocytes)¹³. Accordingly, HBV DNA integration cannot be increased by simply culturing cells for a longer period.

In general, methods previously used to detect integrated HBV DNA, including Southern blot hybridization¹⁹⁻²³, Alu-PCR^{24,25}, cassette-mediated ligation PCR²⁶, and whole genome sequencing²⁷⁻³¹, do not have the sensitivity to detect single-copies of integrations. We and other researchers have used inverse nested PCR (invPCR) to detect hepadnaviral DNA integration in duck, woodchuck, and human infected livers^{13,14,16,32-35}. Others have introduced procedural modifications to the invPCR technique that may alter the generation of false-positive signals and

restrict the ability for quantification³⁶. If carried out as described in this protocol, invPCR represents a specific and sensitive assay that identifies and quantifies (in absolute copy numbers) multiple HBV DNA integrations. The HBV-cell DNA junction is sequenced at a single-base pair resolution, allowing bioinformatical studies of viral and host DNA sequences at the sites of integration¹³.

We have previously described³⁷ results from invPCR on DNA of HBV-infected tissue extracted from a large range of sources, including snap-frozen liver tissues, paraffin-embedded liver sections, and extremely small tissue samples isolated by laser-microdissection¹⁷. This protocol outlines an updated version of an invPCR assay using DNA extracted from cell culture-derived tissues after *in vitro* infection, in which low copy numbers of integrations (1-2 copies per integration) are generated. The HBV DNA integrations formed *in vitro* resemble those found in patient tissues with respect to their distribution over the cellular genome and junction within the viral sequence that is integrated¹³, suggesting a comparable pathway to within an infected liver.

PROTOCOL:

1. Cell Infection and DNA Extraction

1.1. Maintain cultured Huh7-NTCP cells^{8,9} in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% v/v fetal bovine serum, 1x Penicillin/Streptomycin, and 2 mM L-glutamine.

Note: This has previously been reported in detail³⁸.

1.2. Seed 2×10^5 cells/mL Huh7-NTCP cells into a 12-well plate with 1 mL of DMEM.

1.3. If testing cell treatments (*e.g.*, HBV inhibitors), apply them to the culture supernatant 4 h after seeding (1 day prior to HBV infection). For a negative control, apply 200 nM Myrcludex B (a potent HBV entry inhibitor³⁹).

1.4. Use heparin-column purified⁴⁰ supernatant from HepAD38⁴¹ as an inoculum to infect cells at 1000 VGE/cell in 500 μ L of culture media (DMEM supplemented with 10% v/v fetal bovine serum, 1x Penicillin/Streptomycin, 2 mM L-glutamine, and 2.5% v/v DMSO), containing 4% w/v polyethylene glycol 8000 [dissolved in 1x phosphate-buffered saline (PBS)].

1.5. Culture the cells in a 37 °C incubator (set at 5% CO₂ and 90% humidity).

1.6. Wash the cells twice with 1 mL of sterile 1x PBS at 16-24 h post-infection.

1.7. Replace the culture media every 2 days following HBV infection until harvest.

1.8. At day 3 post-infection, treat the cells with 5 μ M Tenofovir disoproxil and 10 μ M Lamivudine to limit production of HBV replicative intermediates that are amplifiable by invPCR.

1.9. At day 5 post-infection, trypsinize the cells with 200 μ L of Trypsin-EDTA and resuspend them in 2 mL of DMEM (supplemented with 10% v/v fetal bovine serum, 1x Penicillin/Streptomycin, and 2mM L-glutamine), also containing 5 μ M Tenofovir disoproxil and 10 μ M Lamivudine.

1.10. Transfer the cell suspensions to a 6-well plate to induce one round of mitosis (which has been reported to induce loss of HBV cccDNA⁴² and other HBV DNA intermediates that are amplifiable by invPCR).

1.11. At day 7 post-infection, trypsinize the expanded cells in 400 μ L of Trypsin-EDTA and resuspend the mixture in 1 mL of DMEM. Place the suspension in a 1.5 mL tube, pellet the cells by centrifugation at 500 x g for 5 min, and remove the supernatant by aspiration.

1.12. (Optional) Store the cell pellets at -20 °C until they are ready for DNA extraction.

1.13. Extract the DNA from the cell pellet using a DNA extraction kit, as per the manufacturer's instructions. Estimate the final DNA concentration using optical densitometry.

Note: The DNA yield in a 100 μ L elution volume is generally ~250-400 ng/ μ L.

2. Inversion of DNA

2.1. Aliquot ~1.5-2.5 μ g of the total DNA extract from step 1 into a 200 μ L PCR tube. Add the appropriate amount of restriction enzyme master-mix to result in a 40 μ L reaction volume containing 1x double digest reaction buffer (*e.g.*, CutSmart buffer) and 10 U *Nco*I-HF.

2.2. Mix the reactions thoroughly and spin down in a small tube centrifuge. Incubate the restriction enzyme reaction in a PCR machine at 37 °C for 1 h for optimal digestion efficiency.

2.3. Inactivate the restriction enzyme by incubating at 80 °C for 20 min.

2.4. Transfer the entire restriction enzyme reaction to a 1.5 mL tube. Add 400 μ L of 1x T4 DNA ligase buffer and 500 U of T4 DNA ligase and mix it thoroughly. The large reaction volume encourages intra-molecular (as opposed to inter-molecular) ligation of the digested DNA fragments.

2.5. Incubate the ligation reaction at room temperature for 2 h to ensure complete ligation.

2.6. Inactivate the T4 DNA ligase at 70 °C for 20 min.

2.7. Add 10 μ L of 10% w/v sodium dodecyl sulfate to ensure complete inactivation of the T4 ligase.

2.8. Mix the tubes by pulse vortexing and briefly spin down the reaction mix. Add NaCl to a final concentration of 100 mM and dextran (35-45 kDa) to a final concentration of 90 µg/mL. Mix the tubes by pulse vortexing and briefly spin down the reaction mix.

2.9. Add 900 µL of 100% ethanol and mix by inversion. Precipitate the DNA at -20 °C overnight.

2.10. Pellet the precipitated DNA by centrifugation at 14,000 x g for 15 min. Remove the supernatant by aspiration with a P200 pipette. Wash the pellet with 500 µL of 70% v/v ethanol and centrifugation at 14,000 x g for 15 min.

2.11. Remove the ethanol by aspiration with a P200 pipette. Air-dry the DNA pellet at room temperature for 20 min.

2.12. Dissolve the pellet in 20 µL of H₂O. Add 20 µL of a restriction enzyme master-mix to result in a 40 µL reaction volume containing 1x double digest reaction buffer, 5 U of *Bsi*HKAI, and 5 U of *Sph*I-HF. Incubate the restriction enzyme reaction in a heat-block at 37 °C (the optimal temperature for *Sph*I-HF) for 1 h.

2.13. Briefly spin down the reaction mix. Incubate the restriction enzyme reaction in a heat-block at 65 °C (the optimal temperature for *Bsi*HKAI) for 1 h.

2.14. Briefly spin down the reaction mix.

2.15. Store the inverted DNA at -20 °C until the next step.

3. Nested PCR

3.1. Remove potential amplicons from a reusable silicon mat seal using a DNA degradation solution, rinse the mat thoroughly with DNA-free water, and air-dry it at room temperature while preparing the PCR mixture.

3.2. Prepare 1 mL of a 1x PCR mix containing the outer forward (5'-TTC GCT TCA CCT CTG CAC G-3') and reverse (5'-AAA GGA CGT CCC GCG CAG-3') primers at a concentration of 0.5 µM.

3.3. Add 170 µL of the 1x PCR mix to wells A1 and E1 in a 96-well PCR plate.

3.4. Add 120 µL of the 1x PCR mix to wells B1 to H1.

3.5. Add 10 µL of the inverted DNA from step 2 to wells A1 and E1 (2 different inverted samples can be analyzed on the same PCR plate). Mix the reaction in each well by gently pipetting each about 10 times using a P1000 set to 100 µL.

3.6. Serially dilute samples from wells A1 to D1 at a ratio of 1:3 by transferring 60 μL at each step. Mix the wells at each step by gently pipetting them about 10 times using a P1000 set to 100 μL . Avoid forming bubbles. Repeat step 3.6 for well E1, diluting down to well H1.

3.7. Aliquot 10 μL of the reaction mixture using a multi-channel pipette from wells A1-H1 into wells A2-H2, A3-H3, and so on until reaching wells A12-H12 of the 96-well plate. Cover the PCR plate with the dry silicon mat from step 3.1, pressing firmly.

3.8. Place the plate in a PCR machine and run the following program: 10 min at 95 $^{\circ}\text{C}$; 35 cycles of 15 s at 95 $^{\circ}\text{C}$, 15 s at 54 $^{\circ}\text{C}$ and 3 min at 72 $^{\circ}\text{C}$; 7 min at 72 $^{\circ}\text{C}$; then, hold the plate at room temperature.

3.9. Heat the pins of a 96-pin replicator to red-hot with a Bunsen burner and then cool for at least 5 min at room temperature.

3.10. Fill the wells of a second PCR plate with 10 μL of 1x PCR mix (containing a gel load-ready buffer) and the inner forward (5'-CGC ATG GAG ACC ACC GTG A-3') and reverse (5'-CAC AGC CTA GCA GCC ATG G-3') at 0.5 μM .

3.11. Carefully remove the silicon mat from the PCR plate of the 96-well plate from the first-round PCR, and avoid cross-contamination between wells.

3.12. Use the cooled replicator to transfer the PCR products of the 96-well plate from first-round PCR to the newly-aliquoted 96-well plate. Carry out the nested PCR using the same conditions as in step 3.8, except for changing the initial denaturation step at 95 $^{\circ}\text{C}$ from 10 min to 2 min.

4. PCR Product Isolation and Gel Extraction

4.1. Analyze the PCR products by gel electrophoresis using a 96-well with 1.3% w/v agarose gel. For a 100 mL agarose gel, run at 200 V for 10-15 min.

4.2. Excise the DNA bands from the agarose gels using disposable drinking straws. For each PCR product, place the straw and agarose gel plug into a 1.5 mL tube and trim the straw to size with scissors.

Note: It is sufficient to isolate bands only from those dilutions in which single PCR products can be resolved.

4.3. (Optional) Store the tubes at -20 $^{\circ}\text{C}$ for later extraction.

4.4. Eject the agarose plugs into each tube by squeezing on the end of the straw fragment. Add 300 μL of gel extraction buffer and 5 μL of gel extraction glass bead slurry to each tube.

4.5. Extract the PCR products as per the manufacturer's instructions for the gel extraction kit (except using half-volumes for washing steps) and elute the DNA from the beads with 30 µL of water.

4.6. Submit the purified DNA for Sanger sequencing (as per the supplier's instructions) with the Forward primer used in the second-round nested PCR.

5. Sequence Analysis

5.1. Confirm virus-cell DNA junctions by performing nucleotide BLAST analysis (using default settings aligning to the entire nucleotide collection).

Note: Representative results are detailed in **Figure 3** below.

5.1.1. If only partial alignment of the sequence is observed, trim the 5' HBV DNA sequence before re-running a BLAST analysis.

5.2. Apply stringent selection criteria to determine if a given sequence represents a true integration junction as follows:

5.2.1. Include only sequences containing >20 bp of a cellular sequence for confident mapping to the cellular genome.

5.2.2. Disregard any sequences that contain restriction sites of any enzymes used within 10 bp of the supposed virus-cell integration junction, as they likely represent *in vitro* ligation events rather than true integration junctions.

5.2.3. Disregard any sequences with obvious dissimilar peak fluorescence levels on either side of the supposed integration junction in sequencing chromatographs, as these are likely artifacts generated by cross-contamination during the sequencing reaction or capillary chromatography.

5.2.4. Define unique integration events as those with the exact HBV and cellular sequences at the virus-cell junction.

Note: Repetition of unique integration events can result from clonal expansion of cells containing those integrations or cross-contamination during the PCR (which can be tested using negative-control reactions, further detailed in the representative results below). Repeated integrations into specific cellular sequences are expected to display different HBV terminal sites for each integration event, as non-homologous end-joining pathways are used¹⁵.

5.3. Calculate the integration frequency by multiplying the dilution factor of inverted DNA templates by the number of virus-cell junctions detected at that dilution, followed by normalization to the amount of total DNA input into the inversion reaction. Generally, the integration frequency is on the order of 1:10⁴ cells.

REPRESENTATIVE RESULTS:

A schematic representation of the invPCR technique is shown in **Figure 1**. An example agarose gel electrophoresis of a successful invPCR is shown in **Figure 2** before and after the PCR product isolation. **Figure 3** shows the BLAST analysis output from step 5.1 in the cases of (i) amplification of virus-cell DNA junction and (ii) amplification of an HBV DNA replicative intermediate.

Expected results from positive controls: Huh7-NTCP cells infected with heparin-purified HBV stocks as described above (**Figure 1**) can serve as a positive control. In this instance, single PCR products should be achieved by the second or third 1:3 dilution of each sample (corresponding to $\sim 10^4$ cell equivalents per dilution, **Figure 2**). At these dilutions, approximately 50% of products will represent true virus-cell DNA junctions, while the other half represents amplification of HBV DNA intermediates (**Figure 3**).

In previous studies¹³, we have found few instances of repeated virus-cell junctions, suggesting no cellular genomic sites of preferential HBV DNA integration. We also find that >80% of virus-cell junctions occur between nucleotides 1732 and 1832 (according to the nucleotide numbering of HBV genotype D, GenBank Accession #U95551.1), where the latter represents the right-hand terminus of the HBV dsDNA form. Sequences of true virus-cell junctions found through our method in *in vitro* experiments are publicly available on GenBank (Accession numbers MH057851 to MH058006).

Expected results from negative controls: Either uninfected Huh7-NTCP cells or inoculated Huh7-NTCP cells pre-treated with Myrcludex B can act as negative controls. InvPCR analysis of DNA extracted from these cells should produce no PCR products. Running these negative-control samples on the same PCR plate as positive samples allows for testing of cross-contamination during the nested-PCR process. The most stringent test for cross-contamination is the running of a negative-control sample in wells A-D and the positive sample in wells E-H on a 96-well plate. In this case, the most concentrated dilution of the positive sample is run in a row directly adjacent to the least concentrated dilution of the negative sample. If amplification products are observed in negative-control samples, institute the measures suggested in the discussion to minimize cross-contamination events.

FIGURE LEGENDS:

Figure 1: Schematic figure of the invPCR process to detect HBV DNA integrations. After HBV infection, only a minority of Huh7-NTCP cells contain HBV dsDNA (red) integrated into the host cell genome (red), depicted in the top section. Total DNA is then extracted from the cells (step 1), inverted (step 2), and amplified by nested PCR (step 3). Shown are the relative positions of the restriction enzyme sites (*Nco*I and *Bsi*HKAI) in the excised virus-cell DNA junction. The figure is adapted from a previous publication¹³.

Figure 2: Agarose gel electrophoresis and subsequent gel extraction of a successful invPCR. “M” represents DNA marker ladder. Each row of 12 represents technical replicates at a single dilution

on the PCR plate. Two inverted DNA samples can be run per PCR plate/agarose gel. The PCR products for each dilution should titrate out in a ~1:3 ratio. Extraction of the products from the two least concentrated dilutions where single bands can be easily isolated is generally sufficient, as HBV DNA integration rate is determined by end-point titration.

Figure 3: BLAST analysis of invPCR product sequences. As long tracts of sequence are generated from Sanger sequencing, the source of DNA sequences is generally unambiguous. Strong alignment to HBV and cellular genomes is observed in different areas of the FASTA sequence file generated from Sanger sequencing in the top panel, suggesting a true virus-cell DNA junction. In the bottom panel, the sequence aligns only to fragments of the HBV genome, suggesting a product generated by the amplification of a rearranged HBV DNA genome.

DISCUSSION:

Before performing the protocol, it is important to note that this invPCR assay is a highly sensitive technique, capable of amplifying single copies of DNA template. Therefore, limiting contamination from PCR products is of utmost importance. General strategies to limit PCR product contamination include the following. (i) Establish physically separate areas for different steps of the method. Each area should have separate lab coats, and gloves should be changed when moving between these areas. We have listed these areas below in order from most to least likely to be contaminated: PCR product extraction and sequencing reaction set-up area (post-PCR); PCR template addition and flamed-pin transfer area (we have used PCR hoods with a decontaminating UV lamp with good results); DNA extraction and inversion area (pre-PCR); and a “DNA template-free” area used solely for preparing stock and PCR solutions. (ii) Be aware of air flow in the lab as a potential driver of cross-contamination. In particular, cross-contamination of PCR reactions during the flamed pin transfer step is most likely to occur and will lead to inaccurate quantification of integration frequency. PCR hoods can be used to limit these cross-currents. Negative control wells (*e.g.*, Myrcludex B-treated samples or no template controls) in the PCR can be also used to test for cross-contamination. (iii) Limit potential PCR contaminants on pipettes and work surfaces by regularly wiping them down with a DNA degradation solution.

The protocol specified here is arranged to detect integration of a known infectious HBV clone generated from the HepAD38 cell line⁴¹. If the inoculum used is of a different HBV DNA sequence (*e.g.*, from patient serum), then the HBV genome should be first sequenced to confirm compatibility of PCR primers and inversion design. In previously published studies³⁵, we have used 3 sets of primers that bind conserved HBV DNA sequences flanking the expected site of HBV DNA integration junctions. Other primer sequences and protocols have been described to determine the genomic sequence of HBV⁴³⁻⁴⁷ and may work successfully.

Furthermore, different HBV-susceptible cells (*e.g.*, primary human hepatocytes, differentiated HepaRG, HepG2-NTCP cells) can be used; however, we have found that Huh7-NTCP cells provide the greatest signal-to-noise ratio, when considering the number of virus-cell DNA junctions that are amplified compared to the virus intermediate DNA that is amplified¹³. In particular, terminally differentiated cells such as primary human hepatocytes or differentiated HepaRG do not efficiently undergo mitosis, resulting in a high level of amplifiable HBV DNA replicative

intermediates remaining within the cells. We have found that ~90% of amplified sequences represent HBV DNA rearrangements (and not integration events) in terminally-differentiated cells, compared to 70-50% in hepatoma cell lines¹³. These products are generally HBV DNA genomes containing large deletions in the surface and core open reading frames, or they can represent HBV quasi-species with an additional *Nco*I site prior to the *Sph*I site. The amplification of these HBV species (including a schematic diagram) have been described in detail previously¹³.

There are several drawbacks to this method. Due to the laborious and multi-day nature of this protocol, invPCR is not suited to high-throughput analyses of a large number of samples. Furthermore, as it relies on limiting dilution titration, our method is not highly precise in quantification; although, it should easily to differentiate between log-level changes in integration frequency.

Moreover, our inversion protocol is only suited to detect integrations occurring between the DR2 and DR1 region of the HBV genome, as the majority of HBV integrations occur within this region⁴⁸. NGS analysis of HBV patient tissues has shown that a large minority (up to ~50%) may also occur outside of this region⁴⁸. New invPCR designs are theoretically able to detect these other integration sites, though they have not (to our knowledge) been carried out yet. Relatedly, due to the necessary restriction enzyme sites required downstream from the virus-cell junction sequence for the inversion reaction, invPCR does not detect all integrations occurring within the DR2 and DR1 regions of the HBV genome (*i.e.*, we have estimated that ~10% of all integrations are detectable using *in silico* simulations¹³). However, when applied to a focused batch of samples with small numbers of different treatments, invPCR is one of the only practical methods for detecting integrated HBV DNA at a single base-pair resolution.

We therefore envision applications of this method serving a key role in finding viral (via mutations of the HBV inoculum), cellular (through knockout or overexpression of specific cellular genes, or through application of various drugs), and environmental (*e.g.*, exposure to oxidative stress) factors that induce HBV DNA integration. With this method and newly developed HBV infection systems, we enable unprecedented control of these factors so that they can be well-isolated and better characterized. We also expect that this will lead to a key understanding of the cellular consequences of HBV DNA integration, including to what extent viral antigens (*e.g.*, HBx or HBsAg⁴⁹) are expressed from the integrated form, what controls this expression, and whether or not HBV integration significantly changes the cellular phenotype towards a more pro-oncogenic state. The results of these future studies will have a profound impact on the therapeutic strategies used to treat chronic hepatitis B and on the basic understanding of the virus itself.

ACKNOWLEDGMENTS

This work received funding from the German Centre for Infection Research (DZIF), TTU Hepatitis Projects 5.807 and 5.704, the Deutsche Forschungsgemeinschaft (DFG) TRR179 (TP 15), and the Australian Centre for HIV and Hepatitis Virology Research.

We are indebted to Professor William Mason for his part in developing the original invPCR method and demonstrating it to us. We would like to thank Drs. Yi Ni and Florian A. Lempp for

reagents (cell lines and HBV inoculum). We acknowledge Anja Rippert, Franziska Schlund, Sarah Engelhardt, and Dr. Katrin Schöneweis for technical assistance. We are grateful to Miriam Kleinig for proofreading, and to Professors Nicholas Shackel and Ralf Bartenschlager for continuous support.

DISCLOSURES

S.U. is a co-applicant and co-inventor of patents protecting Myrcludex B as an HBV/HDV entry inhibitor. T.T. declares no conflicts of interest.

REFERENCES:

- 1 Lin, X., *et al.* Chronic hepatitis B virus infection in the Asia-Pacific region and Africa: review of disease progression. *Journal of Gastroenterology and Hepatology*. **20** (6), 833-843 (2005).
- 2 Illoeje, U. H., *et al.* Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. *Gastroenterology*. **130** (3), 678-686 (2006).
- 3 Huang, Y. T., *et al.* Lifetime risk and sex difference of hepatocellular carcinoma among patients with chronic hepatitis B and C. *Journal of Clinical Oncology*. **29** (27), 3643-3650 (2011).
- 4 Nassal, M. HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B. *Gut*. **64** (12), 1972-1984 (2015).
- 5 Tu, T., Budzinska, M. A., Shackel, N. A., Jilbert, A. R. Conceptual models for the initiation of hepatitis B virus-associated hepatocellular carcinoma. *Liver International*. **35** (7), 1786-1800 (2015).
- 6 Tu, T., Buhler, S., Bartenschlager, R. Chronic viral hepatitis and its association with liver cancer. *Biological Chemistry*. **398** (8), 817-837 (2017).
- 7 Tu, T., Budzinska, M. A., Shackel, N. A., Urban, S. HBV DNA Integration: Molecular Mechanisms and Clinical Implications. *Viruses*. **9** (4) (2017).
- 8 Yan, H., *et al.* Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. *eLife*. **1**, e00049 (2012).
- 9 Ni, Y., *et al.* Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes. *Gastroenterology*. **146** (4), 1070-1083 (2014).
- 10 Tuttleman, J. S., Pourcel, C., Summers, J. Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells. *Cell*. **47** (3), 451-460 (1986).
- 11 Staprans, S., Loeb, D. D., Ganem, D. Mutations affecting hepadnavirus plus-strand DNA synthesis dissociate primer cleavage from translocation and reveal the origin of linear viral DNA. *Journal of Virology*. **65** (3), 1255-1262 (1991).
- 12 Wang, G. H., Seeger, C. The reverse transcriptase of hepatitis B virus acts as a protein primer for viral DNA synthesis. *Cell*. **71** (4), 663-670 (1992).
- 13 Tu, T., Budzinska, M. A., Vondran, F. W. R., Shackel, N. A., Urban, S. Hepatitis B virus DNA integration occurs early in the viral life cycle in an in vitro infection model via NTCP-dependent uptake of enveloped virus particles. *Journal of Virology*. (2018).
- 14 Yang, W., Summers, J. Integration of hepadnavirus DNA in infected liver: evidence for a linear precursor. *Journal of Virology*. **73** (12), 9710-9717 (1999).
- 15 Bill, C. A., Summers, J. Genomic DNA double-strand breaks are targets for hepadnaviral DNA integration. *Proceedings of the National Academy of Sciences of the United States of*

481 *America*. **101** (30), 11135-11140 (2004).

482 16 Mason, W. S., Liu, C., Aldrich, C. E., Litwin, S., Yeh, M. M. Clonal expansion of normal-
 483 appearing human hepatocytes during chronic hepatitis B virus infection. *Journal of Virology*. **84**
 484 (16), 8308-8315 (2010).

485 17 Tu, T., *et al.* Clonal expansion of hepatocytes with a selective advantage occurs during all
 486 stages of chronic hepatitis B virus infection. *Journal of Viral Hepatitis*. **22** (9), 737-753 (2015).

487 18 Mason, W. S., *et al.* HBV DNA Integration and Clonal Hepatocyte Expansion in Chronic
 488 Hepatitis B Patients Considered Immune Tolerant. *Gastroenterology*. **151** (5), 986-998 e984
 489 (2016).

490 19 Shafritz, D. A., Shouval, D., Sherman, H. I., Hadziyannis, S. J., Kew, M. C. Integration of
 491 hepatitis B virus DNA into the genome of liver cells in chronic liver disease and hepatocellular
 492 carcinoma. Studies in percutaneous liver biopsies and post-mortem tissue specimens. *New*
 493 *England Journal of Medicine*. **305** (18), 1067-1073 (1981).

494 20 Hino, O., *et al.* Detection of hepatitis B virus DNA in hepatocellular carcinomas in Japan.
 495 *Hepatology*. **4** (1), 90-95 (1984).

496 21 Fowler, M. J., *et al.* Integration of HBV-DNA may not be a prerequisite for the maintenance
 497 of the state of malignant transformation. An analysis of 110 liver biopsies. *Journal of Hepatology*.
 498 **2** (2), 218-229 (1986).

499 22 Chen, J. Y., Harrison, T. J., Lee, C. S., Chen, D. S., Zuckerman, A. J. Detection of hepatitis B
 500 virus DNA in hepatocellular carcinoma: analysis by hybridization with subgenomic DNA
 501 fragments. *Hepatology*. **8** (3), 518-523 (1988).

502 23 Esumi, M., Tanaka, Y., Tozuka, S., Shikata, T. Clonal state of human hepatocellular
 503 carcinoma and non-tumorous hepatocytes. *Cancer Chemotherapy and Pharmacology*. **23 Suppl**,
 504 S1-3 (1989).

505 24 Murakami, Y., *et al.* Large scaled analysis of hepatitis B virus (HBV) DNA integration in HBV
 506 related hepatocellular carcinomas. *Gut*. **54** (8), 1162-1168 (2005).

507 25 Kimbi, G. C., Kramvis, A., Kew, M. C. Integration of hepatitis B virus DNA into chromosomal
 508 DNA during acute hepatitis B. *World Journal of Gastroenterology*. **11** (41), 6416-6421 (2005).

509 26 Tamori, A., *et al.* Alteration of gene expression in human hepatocellular carcinoma with
 510 integrated hepatitis B virus DNA. *Clinical Cancer Research*. **11** (16), 5821-5826 (2005).

511 27 Sung, W. K., *et al.* Genome-wide survey of recurrent HBV integration in hepatocellular
 512 carcinoma. *Nature Genetics*. **44** (7), 765-769 (2012).

513 28 Fujimoto, A., *et al.* Whole-genome sequencing of liver cancers identifies etiological
 514 influences on mutation patterns and recurrent mutations in chromatin regulators. *Nature*
 515 *Genetics*. **44** (7), 760-764 (2012).

516 29 Jiang, S., *et al.* Re-evaluation of the Carcinogenic Significance of Hepatitis B Virus
 517 Integration in Hepatocarcinogenesis. *Proceedings of the National Academy of Sciences of the*
 518 *United States of America*. **7** (9), e40363 (2012).

519 30 Jiang, Z., *et al.* The effects of hepatitis B virus integration into the genomes of
 520 hepatocellular carcinoma patients. *Genome Research*. **22** (4), 593-601 (2012).

521 31 Kan, Z., *et al.* Whole-genome sequencing identifies recurrent mutations in hepatocellular
 522 carcinoma. *Genome Research*. **23** (9), 1422-1433 (2013).

523 32 Summers, J., *et al.* Hepatocyte turnover during resolution of a transient hepadnaviral
 524 infection. *Proceedings of the National Academy of Sciences of the United States of America*. **100**

(20), 11652-11659 (2003).

33 Mason, W. S., Jilbert, A. R., Summers, J. Clonal expansion of hepatocytes during chronic woodchuck hepatitis virus infection. *Proceedings of the National Academy of Sciences of the United States of America*. **102** (4), 1139-1144 (2005).

34 Mason, W. S., *et al.* Detection of clonally expanded hepatocytes in chimpanzees with chronic hepatitis B virus infection. *Journal of Virology*. **83** (17), 8396-8408 (2009).

35 Tu, T., *et al.* Clonal expansion of hepatocytes with a selective advantage occurs during all stages of chronic hepatitis B virus infection. *Journal of Viral Hepatitis*. (2015).

36 Chauhan, R., Churchill, N. D., Mulrooney-Cousins, P. M., Michalak, T. I. Initial sites of hepadnavirus integration into host genome in human hepatocytes and in the woodchuck model of hepatitis B-associated hepatocellular carcinoma. *Oncogenesis*. **6** (4), e317 (2017).

37 Tu, T., Jilbert, A. R. Detection of Hepatocyte Clones Containing Integrated Hepatitis B Virus DNA Using Inverse Nested PCR. *Methods in Molecular Biology*. **1540**, 97-118 (2017).

38 Ni, Y., Urban, S. Hepatitis B Virus Infection of HepaRG Cells, HepaRG-hNTCP Cells, and Primary Human Hepatocytes. *Methods in Molecular Biology*. **1540**, 15-25 (2017).

39 Schulze, A., Schieck, A., Ni, Y., Mier, W., Urban, S. Fine mapping of pre-S sequence requirements for hepatitis B virus large envelope protein-mediated receptor interaction. *Journal of Virology*. **84** (4), 1989-2000 (2010).

40 Lempp, F. A., *et al.* Evidence that hepatitis B virus replication in mouse cells is limited by the lack of a host cell dependency factor. *Journal of Hepatology*. **64** (3), 556-564 (2016).

41 Ladner, S. K., *et al.* Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication. *Antimicrobial Agents and Chemotherapy*. **41** (8), 1715-1720 (1997).

42 Allweiss, L., *et al.* Proliferation of primary human hepatocytes and prevention of hepatitis B virus reinfection efficiently deplete nuclear cccDNA in vivo. *Gut*. (2017).

43 Yang, Z. T., *et al.* Characterization of Full-Length Genomes of Hepatitis B Virus Quasispecies in Sera of Patients at Different Phases of Infection. *Journal of Clinical Microbiology*. **53** (7), 2203-2214 (2015).

44 Chook, J. B., *et al.* Universal Primers for Detection and Sequencing of Hepatitis B Virus Genomes across Genotypes A to G. *Journal of Clinical Microbiology*. **53** (6), 1831-1835, doi:10.1128/JCM.03449-14, (2015).


45 Li, F., *et al.* Whole genome characterization of hepatitis B virus quasispecies with massively parallel pyrosequencing. *Clinical Microbiology and Infection*. **21** (3), 280-287 (2015).


46 Zhou, T. C., *et al.* Evolution of full-length genomes of HBV quasispecies in sera of patients with a coexistence of HBsAg and anti-HBs antibodies. *Scientific Reports*. **7** (1), 661 (2017).

47 Long, Q. X., Hu, J. L., Huang, A. L. Deep Sequencing of the Hepatitis B Virus Genome: Analysis of Multiple Samples by Implementation of the Illumina Platform. *Methods in Molecular Biology*. **1540**, 211-218 (2017).

48 Li, X., *et al.* The function of targeted host genes determines the oncogenicity of HBV integration in hepatocellular carcinoma. *Journal of Hepatology*. **60** (5), 975-984 (2014).

49 Wooddell, C. I., *et al.* RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg. *Science Translational Medicine*. **9** (409), (2017).





Band isolation




Figure 3

Virus-cell junction



Virus-virus product



Name of Material/ Equipment	Company	Catalog Number	Comments/Description
Dulbecco's PBS	PAA	H15-002	
	Thermo Fisher		
DMEM medium	Scientific	41965	
Fetal bovine serum	PAA	A15-151	Heat-inactivate before use
Penicillin, 10000U/ml; Streptomycin			
10mg/ml, 100×	PAA	P11-010	
L-glutamine, 200mM	PAA	M11-004	
Trypsin, 0.5 mg/ml; EDTA, 0.22mg/ml,			
1×	PAA	L11-004	
PEG, MW 8000	Sigma-Aldrich	89510	Stock at 40% w/v in 1xPBS, autoclave before use
DMSO for spectroscopy	Merck	102950	
Tenofovir disoproxil	Sigma-Aldrich	CDS021622	Dissolve in DMSO
Lamivudine	Sigma-Aldrich	L1295	Dissolve in DMSO
NucleoSpin Tissue kit	Macherey Nagel	740952.250	
NanoDrop 2000/2000c	Thermo Fisher		
Spectrophotometer	Scientific	ND-2000	
<i>Nco</i> I-HF	NEB	R3193L	
T4 DNA ligase	NEB	M0202T	
Sodium dodecyl sulfate	Sigma-Aldrich	L3771	
Sodium Chloride	Sigma-Aldrich	433209	
Dextran (35 -45 kDa)	Sigma-Aldrich	D1662-10G	
Absolute Ethanol	Sigma-Aldrich	32205-1L-D	
<i>Bsi</i> HKAI	NEB	R0570L	
<i>Sph</i> I-HF	NEB	R3182L	
	Thermo Fisher		
Amplitaq Gold Taq kit	Scientific	4331816	Use for first nest PCR
Silicon sealing Mats for 96-Well PCR			
Plates	Biorad	2239442	
DNAZap PCR DNA Degradation	Thermo Fisher		
Solution	Scientific	AM9890	
96-well PCR plates	Sigma Aldrich	CLS6509 SIGMA	
	Thermo Fisher		
96-pin replicator	Scientific	250520	

GoTaq Flexi PCR kit
Biozym LE Agarose
QIAEX II Gel extraction kit

Promega
Biozym
QIAGEN

M8295
840004
20051

Use for second nest PCR, use green buffer for easy
loading of agarose gel



1 Alewife Center #200
Cambridge, MA 02140
tel. 617.945.9051
www.jove.com

ARTICLE AND VIDEO LICENSE AGREEMENT

Title of Article:

DETECTION OF LOW COPY NUMBER INTEGRATED VIRAL DNA FORMED BY IN VITRO
HEPATITIS B VIRUS INFECTION.

Author(s):

THOMAS TU, STEPHAN URBAN.

Item 1 (check one box): The Author elects to have the Materials be made available (as described at
<http://www.jove.com/author>) via: ☐ Standard Access ☒ Open Access

Item 2 (check one box):

- ☒ The Author is NOT a United States government employee.
- ☐ The Author is a United States government employee and the Materials were prepared in the course of his or her duties as a United States government employee.
- ☐ The Author is a United States government employee but the Materials were NOT prepared in the course of his or her duties as a United States government employee.

ARTICLE AND VIDEO LICENSE AGREEMENT

1. **Defined Terms.** As used in this Article and Video License Agreement, the following terms shall have the following meanings: **"Agreement"** means this Article and Video License Agreement; **"Article"** means the article specified on the last page of this Agreement, including any associated materials such as texts, figures, tables, artwork, abstracts, or summaries contained therein; **"Author"** means the author who is a signatory to this Agreement; **"Collective Work"** means a work, such as a periodical issue, anthology or encyclopedia, in which the Materials in their entirety in unmodified form, along with a number of other contributions, constituting separate and independent works in themselves, are assembled into a collective whole; **"CRC License"** means the Creative Commons Attribution-Non Commercial-No Derivs 3.0 Unported Agreement, the terms and conditions of which can be found at: <http://creativecommons.org/licenses/by-nc-nd/3.0/legalcode>; **"Derivative Work"** means a work based upon the Materials or upon the Materials and other pre-existing works, such as a translation, musical arrangement, dramatization, fictionalization, motion picture version, sound recording, art reproduction, abridgment, condensation, or any other form in which the Materials may be recast, transformed, or adapted; **"Institution"** means the institution, listed on the last page of this Agreement, by which the Author was employed at the time of the creation of the Materials; **"JoVE"** means MyJoVE Corporation, a Massachusetts corporation and the publisher of *The Journal of Visualized Experiments*; **"Materials"** means the Article and / or the Video; **"Parties"** means the Author and JoVE; **"Video"** means any video(s) made by the Author, alone or in conjunction with any other parties, or by JoVE or its affiliates or agents, individually or in collaboration with the Author or any other parties, incorporating all or any portion of the Article, and in which the Author may or may not appear.

2. **Background.** The Author, who is the author of the Article, in order to ensure the dissemination and protection of the Article, desires to have the JoVE publish the Article and create and transmit videos based on the Article. In furtherance of such goals, the Parties desire to memorialize in this Agreement the respective rights of each Party in and to the Article and the Video.

3. **Grant of Rights in Article.** In consideration of JoVE agreeing to publish the Article, the Author hereby grants to JoVE, subject to **Sections 4 and 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Article in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Article into other languages, create adaptations, summaries or extracts of the Article or other Derivative Works (including, without limitation, the Video) or Collective Works based on all or any portion of the Article and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. If the "Open Access" box has been checked in **Item 1** above, JoVE and the Author hereby grant to the public all such rights in the Article as provided in, but subject to all limitations and requirements set forth in, the CRC License.

ARTICLE AND VIDEO LICENSE AGREEMENT

4. Retention of Rights in Article. Notwithstanding the exclusive license granted to JoVE in **Section 3** above, the Author shall, with respect to the Article, retain the non-exclusive right to use all or part of the Article for the non-commercial purpose of giving lectures, presentations or teaching classes, and to post a copy of the Article on the Institution's website or the Author's personal website, in each case provided that a link to the Article on the JoVE website is provided and notice of JoVE's copyright in the Article is included. All non-copyright intellectual property rights in and to the Article, such as patent rights, shall remain with the Author.

5. Grant of Rights in Video – Standard Access. This **Section 5** applies if the "Standard Access" box has been checked in **Item 1** above or if no box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby acknowledges and agrees that, Subject to **Section 7** below, JoVE is and shall be the sole and exclusive owner of all rights of any nature, including, without limitation, all copyrights, in and to the Video. To the extent that, by law, the Author is deemed, now or at any time in the future, to have any rights of any nature in or to the Video, the Author hereby disclaims all such rights and transfers all such rights to JoVE.

6. Grant of Rights in Video – Open Access. This **Section 6** applies only if the "Open Access" box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby grants to JoVE, subject to **Section 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Video in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Video into other languages, create adaptations, summaries or extracts of the Video or other Derivative Works or Collective Works based on all or any portion of the Video and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. For any Video to which this Section 6 is applicable, JoVE and the Author hereby grant to the public all such rights in the Video as provided in, but subject to all limitations and requirements set forth in, the CRC License.

7. Government Employees. If the Author is a United States government employee and the Article was prepared in the course of his or her duties as a United States government employee, as indicated in **Item 2** above, and any of the licenses or grants granted by the Author hereunder exceed the scope of the 17 U.S.C. 403, then the rights granted hereunder shall be limited to the maximum rights permitted under such

statute. In such case, all provisions contained herein that are not in conflict with such statute shall remain in full force and effect, and all provisions contained herein that do so conflict shall be deemed to be amended so as to provide to JoVE the maximum rights permissible within such statute.

8. Likeness, Privacy, Personality. The Author hereby grants JoVE the right to use the Author's name, voice, likeness, picture, photograph, image, biography and performance in any way, commercial or otherwise, in connection with the Materials and the sale, promotion and distribution thereof. The Author hereby waives any and all rights he or she may have, relating to his or her appearance in the Video or otherwise relating to the Materials, under all applicable privacy, likeness, personality or similar laws.

9. Author Warranties. The Author represents and warrants that the Article is original, that it has not been published, that the copyright interest is owned by the Author (or, if more than one author is listed at the beginning of this Agreement, by such authors collectively) and has not been assigned, licensed, or otherwise transferred to any other party. The Author represents and warrants that the author(s) listed at the top of this Agreement are the only authors of the Materials. If more than one author is listed at the top of this Agreement and if any such author has not entered into a separate Article and Video License Agreement with JoVE relating to the Materials, the Author represents and warrants that the Author has been authorized by each of the other such authors to execute this Agreement on his or her behalf and to bind him or her with respect to the terms of this Agreement as if each of them had been a party hereto as an Author. The Author warrants that the use, reproduction, distribution, public or private performance or display, and/or modification of all or any portion of the Materials does not and will not violate, infringe and/or misappropriate the patent, trademark, intellectual property or other rights of any third party. The Author represents and warrants that it has and will continue to comply with all government, institutional and other regulations, including, without limitation all institutional, laboratory, hospital, ethical, human and animal treatment, privacy, and all other rules, regulations, laws, procedures or guidelines, applicable to the Materials, and that all research involving human and animal subjects has been approved by the Author's relevant institutional review board.

10. JoVE Discretion. If the Author requests the assistance of JoVE in producing the Video in the Author's facility, the Author shall ensure that the presence of JoVE employees, agents or independent contractors is in accordance with the relevant regulations of the Author's institution. If more than one author is listed at the beginning of this Agreement, JoVE may, in its sole discretion, elect not take any action with respect to the Article until such time as it has received complete, executed Article and Video License Agreements from each such author. JoVE reserves the right, in its absolute and sole discretion and without giving any reason therefore, to accept or decline any work submitted to JoVE. JoVE and its employees, agents and independent contractors shall have

ARTICLE AND VIDEO LICENSE AGREEMENT

full, unfettered access to the facilities of the Author or of the Author's institution as necessary to make the Video, whether actually published or not. JoVE has sole discretion as to the method of making and publishing the Materials, including, without limitation, to all decisions regarding editing, lighting, filming, timing of publication, if any, length, quality, content and the like.

11. **Indemnification.** The Author agrees to indemnify JoVE and/or its successors and assigns from and against any and all claims, costs, and expenses, including attorney's fees, arising out of any breach of any warranty or other representations contained herein. The Author further agrees to indemnify and hold harmless JoVE from and against any and all claims, costs, and expenses, including attorney's fees, resulting from the breach by the Author of any representation or warranty contained herein or from allegations or instances of violation of intellectual property rights, damage to the Author's or the Author's institution's facilities, fraud, libel, defamation, research, equipment, experiments, property damage, personal injury, violations of institutional, laboratory, hospital, ethical, human and animal treatment, privacy or other rules, regulations, laws, procedures or guidelines, liabilities and other losses or damages related in any way to the submission of work to JoVE, making of videos by JoVE, or publication in JoVE or elsewhere by JoVE. The Author shall be responsible for, and shall hold JoVE harmless from, damages caused by lack of sterilization, lack of cleanliness or by contamination due to the making of a video by JoVE its employees, agents or independent contractors. All sterilization, cleanliness or decontamination procedures shall be solely the responsibility of the Author and shall be undertaken at the Author's

expense. All indemnifications provided herein shall include JoVE's attorney's fees and costs related to said losses or damages. Such indemnification and holding harmless shall include such losses or damages incurred by, or in connection with, acts or omissions of JoVE, its employees, agents or independent contractors.

12. **Fees.** To cover the cost incurred for publication, JoVE must receive payment before production and publication the Materials. Payment is due in 21 days of invoice. Should the Materials not be published due to an editorial or production decision, these funds will be returned to the Author. Withdrawal by the Author of any submitted Materials after final peer review approval will result in a US\$1,200 fee to cover pre-production expenses incurred by JoVE. If payment is not received by the completion of filming, production and publication of the Materials will be suspended until payment is received.

13. **Transfer, Governing Law.** This Agreement may be assigned by JoVE and shall inure to the benefits of any of JoVE's successors and assignees. This Agreement shall be governed and construed by the internal laws of the Commonwealth of Massachusetts without giving effect to any conflict of law provision thereunder. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

A signed copy of this document must be sent with all new submissions. Only one Agreement required per submission.


CORRESPONDING AUTHOR:

Name: THOMAS TV.

Department: DEPARTMENT OF INFECTIOUS DISEASES.

Institution: HEIDELBERG UNIVERSITY HOSPITAL.

Article Title: DETECTION OF LOW COPY NUMBER INTEGRATED VIRAL DNA FORMED BY IN VITRO HEPATITIS B VIRUS INFECTION

Signature:  Date: 26/03/2018.

Please submit a signed and dated copy of this license by one of the following three methods:

- 1) Upload a scanned copy of the document as a pdf on the JoVE submission site;
- 2) Fax the document to +1.866.381.2236;
- 3) Mail the document to JoVE / Attn: JoVE Editorial / 1 Alewife Center #200 / Cambridge, MA 02139

For questions, please email submissions@jove.com or call +1.617.945.9051



Medical Faculty Heidelberg

Dr. Thomas Tu | INF 344, 1. OG | D-69120 Heidelberg

To Dr. Jaydev Upponi Ph.D.

Science Editor | Immunology and Infection

Editorial Department

JoVE

1 Alewife Center | Suite 200 | Cambridge | MA 02140 | USA

Email: jaydev.upponi@jove.com

March 27th, 2018

Dear Dr. Upponi,

Thank you for your feedback and review of our manuscript “**Detection of low copy number integrated viral DNA formed by in vitro Hepatitis B Virus infection**” (JoVE58202R1).

We appreciate the time, effort, and comments given by the reviewers and have revised our manuscript to address each of their concerns. We have provided a point-by-point rebuttal below. Further, we have edited some sentences throughout the manuscript to improve clarity. Finally, we have resubmitted our Figures as high-quality .TIF files suitable for publication.

Thank you for considering this work for publication.

Yours sincerely,

Dr. Thomas Tu

University Hospital Heidelberg

Molekular Virologie, Zentrum für Infektiologie

Im Neuenheimer Feld 344

Heidelberg, Baden-Württemberg 69120, Germany



MOLECULAR VIROLOGY
H E I D E L B E R G

Department of Infectious Diseases
Molecular Virology


Dr. Thomas Tu

Im Neuenheimer Feld 344
69120 Heidelberg
Germany

Tel +49 (0)6221 56 4909

Thomas.Tu@med.uni-heidelberg.de

www.molecular-virology.uni-hd.de



Editorial comments:

1. Please take this opportunity to thoroughly proofread the manuscript to ensure that there are no spelling or grammar issues. The JoVE editor will not copy-edit your manuscript and any errors in the submitted revision may be present in the published version.

2. Please use American English.

4. Please remove trademark (™) and registered (®) symbols from the Table of Equipment and Materials.

5. JoVE cannot publish manuscripts containing commercial language. This includes trademark symbols (™), registered symbols (®), and company names before an instrument or reagent. Please remove all commercial language from your manuscript and use generic terms instead. All commercial products should be sufficiently referenced in the Table of Materials and Reagents.

For example: AmpliTaq Gold, Qiagen, Eppendorf, etc.

10. Please do not abbreviate journal titles.

This manuscript has now undergone thorough proofreading and editing. Spelling has been altered to American English throughout the manuscript. In addition, the minor changes with regard to removal of commercial language and full journal titles have been implemented.


Editor, 3. Unfortunately, there are a few sections of the manuscript that show overlap with previously published work. Though there may be a limited number of ways to describe a technique, please use original language throughout the manuscript. Please see lines: 42-44, 54-65, 90-95,

Reviewer 3, Minor Concern:

It is very similar to the paper recently publishes "Hepatitis B virus DNA integration occurs early in the viral life cycle in an in vitro infection model via NTCP-dependent uptake of enveloped virus particles.

Tu T, Budzinska MA, Vondran FWR, Shackel NA, Urban S" in J virol.

As already mentioned in discussions with the editor prior to initiation of writing, this manuscript is an update to a previous protocol description (*Chapter 9 - Detection of Hepatocyte Clones Containing Integrated Hepatitis B Virus DNA Using Inverse Nested*



PCR, Springer Nature, 2017) and the invitation for writing this manuscript was a result of our publication (*Hepatitis B virus DNA integration occurs early in the viral life cycle in an in vitro infection model via NTCP-dependent uptake of enveloped virus particles.*, J Virol, 2018) allowing us to more thoroughly describe our protocol. Therefore, we must necessarily cover much of the same ground as these publications. In some instances, there are only so many wording rearrangements that can be implemented before clarity is sacrificed. Further, some of the terms highlighted represent those commonly used in the Hepatitis B Virus field (e.g. covalently-closed circular DNA) and cannot be rewritten without confusion. With these challenges in mind, we have now re-written these sections as much as possible with original wording.

Editor, 6. Please add more details to your protocol steps. Please ensure you answer the “how” question, i.e., how is the step performed? Alternatively, add references to published material specifying how to perform the protocol action.

We are unsure which specific steps the editor refers to in this comment. We have reviewed each step and feel we have now given ample detail for each step in the revised manuscript (on par with the example manuscript provided to us by the editors).

Editor, 7. 1.1: What are the culture conditions?

We have already provided multiple references for the detailed cell culture conditions to avoid any descriptions that are repeated from previous publications (as was criticised in point 3). Could the editor please outline what specific details are missing in this step?

Editor, 8. Please specify what happens after centrifugation. Aspiration?

We assume the editor refers to a missing step after Step 2.16. We have now added an extra step, which reads as follows: “2.17. Remove the supernatant by aspiration with a P200 pipette.”



Editor, 9. Please expand the Representative Results in the context of the technique you have described, e.g., how do these results show the technique, suggestions about how to analyze the outcome, etc. The paragraph text should refer to all of the figures. Data from both successful and sub-optimal experiments can be included.

We need more than one sentence per figure.

Reviewer #1: How about possibilities of false positive and/or false negative result by invPCR?

Reviewer #4: 3. The authors do not provide descriptions of positive, negative and contamination controls. This should be supplied.

We had followed the format given in the example manuscript sent to us by the editor where only a single sentence was given per figure. We have now added three extra paragraphs in the Representative results (Lines 331-354 in the updated manuscript) regarding expected results in the controls, as well as additional information to analyse sequences for false positive results (Step 5.2., Lines 301-318). If this is not sufficient, it would be helpful to know exactly the structure of the representative results required from us by the editor with another more accurate example.


Reviewer #1: In line 89, in Introduction; cassette ligation PCR is one of the useful method for HBV integration. The below paper should be referred.

Tamori A et al., Alteration of gene expression in human hepatocellular carcinoma with integrated hepatitis B virus DNA.

Clin Cancer Res. 2005; 11: 5821-5826.

Reviewer #4, 6. Regarding introduction (line 76), this reviewer noticed that the authors forgotten to mention that a very similar model applying patient originating HBV and HepaRG cells has been recently established and the applicability of the invPCR approach to detect very early integrations of HBV and woodchuck virus to host genomes have been documented (Oncogenesis 2017). The authors should add this reference.

We apologise for overlooking these studies and have now added these references in Lines 85-91.



Reviewer #2: My only (and very minor) critique is that the "untreated samples" comment in line 314 is a bit vague.

This comment has now been addressed and we have greatly expanded this section with paragraphs describing the expected results from positive samples (lines 331-343):

“Expected results from positive controls


Huh7-NTCP cells infected with heparin-purified HBV stocks as described above (**Figure 1**) can serve as a positive control. In this instance, single PCR products should be achieved by the second or third 1:3 dilution of each sample (corresponding to $\sim 10^4$ cell equivalents per dilution, **Figure 2**). At these dilutions, $\sim 50\%$ of products will represent true virus-cell DNA junctions (**Figure 3A**), while the other half represent amplification of HBV DNA intermediates (**Figure 3B**).

In previous studies¹³, we have found few instances of repeated virus-cell junctions, suggesting no cellular genomic sites of preferential HBV DNA integration. We also find that $>80\%$ of virus-cell junctions occur between nucleotides 1732 and 1832 (according to the nucleotide numbering of HBV genotype D, GenBank Accession #U95551.1), the latter representing the right-hand terminus of the HBV dsDNA form. Sequences of true virus-cell junctions found by our method in *in vitro* experiments are publically available on Genbank (Accession numbers MH057851 to MH058006).”

Reviewer #3: On Figure 3, in addition to the schematic figures, readers may appreciate to get informations on the nature of the genes where insertions are located, same for virus-virus jonctions some more informations may have been provided on what they are.

Reviewer #4, 2. The statement should be made regarding the rate of nonspecific invPCR amplification, i.e., frequency of bands which do not carry virus-host junctions after completion of analysis.

Both of these points have been made in our previous publication and we have had internal discussions on how much to include in this protocol description (particularly as we have sought to minimise repetition with previously-published works, as we have been criticised for by the editor, point 3). We have now added additional sentences to the discussion:




“We have found that ~90% of amplified sequences represent HBV DNA rearrangements (and not integration events) in terminally-differentiated cells, compared to 70-50% in hepatoma cell lines. These products are generally HBV DNA genomes containing large deletions in the surface and core open reading frames, or represent HBV quasispecies with an additional *NcoI* site prior to the *SphI* site. The amplification of these HBV species (including a schematic diagram) have been extensively described in detail previously.”

Reviewer #4, 1. The manuscript does not describe methodology for identification of virus-host junctions at the single bp resolution. Which computational approaches are/have been applied and what are criteria have to be considered during analysis? This additional information should be provided.

Reviewer #4:4. How is a number of positive hits of a particular virus-host junction calculated using the approach described? How can be it learned if a particular junction is a preferable site of HBV integration? Please explain.

A separate section (Section 5, Lines 294-323 in the revised manuscript) has now been added and specifically outlines how virus-cell junctions are determined by BLAST analysis and analysed (with respect to filtration criteria). This section also include a paragraph on the determination of unique integration events and analysis for repeated integration into preferential cellular regions: “Define unique integration events as those with the exact HBV and cellular sequences at the virus-cell junction. Repetition of unique integration events can be due to clonal expansion of cells containing those integrations, or cross-contamination during the PCR (which can be tested using negative-control reactions, further detailed below in the representative results section). Repeated integrations into specific cellular sequences would be expected to display different HBV terminal sites for each integration event as using non-homologous end-joining pathways are used.”

Reviewer #4, 5. The invPCR approach presented is limited to finding junctions fused with relatively small fragment of HBV DNA. Please explain to the audience reasons why this region was originally selected for priming. In addition, please comment whether it



is feasible to design invPCR conditions amplifying host genome junctions with other regions of HBV genome.

We have now outlined the reasons behind this design (and its weaknesses) in the discussion of the revised manuscript (Lines 426-430): “Moreover, our inversion protocol is only suited to detect integrations occurring between the DR2 and DR1 region of the HBV genome as the majority of HBV integrations occur within this region. NGS analysis of HBV patient tissues has showed that a large minority (up to ~50%) may also occur outside of this region⁴⁸. New invPCR designs are theoretically possible to detect these other integration sites, though have not (to our knowledge) been carried out yet.”

Reviewer #4, Minor Concerns: Fig 2 (lower panel) gives an impression that the bands were not completely cut out from gels. Is it artifact or the bands do not need to be removed from gel completely?

In Figure 2, the bands are in fact excised completely. We believe that the lightening around the area of the excision hole that the reviewer refers to is simply an unavoidable artefact caused by UV light reflection against the cut surface and does not represent residual DNA in the gel.